2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo(d)imidazole-4-carboxylic acid,
GSK2636771,
GSK2636771,
1372540-25-4,
GSK-2636771,
2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid,
UNII-DW94IAT0LS,
DW94IAT0LS,
GSK 2636771,
2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid,
2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid,
lic acid,
XTKLTGBKIDQGQL-UHFFFAOYSA-N,
2-Methyl-1-[[2-Methyl-3-(trifluoroMethyl)phenyl]Methyl]-6-(4-Morpholinyl)-1H-benziMidazole-4-carboxylic acid,
2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid,
MLS006011177,
GTPL7967,
SCHEMBL1280998,
CHEMBL3188551,
DTXSID10160124,
EX-A434,
QCR-187,
HMS3653H17,
AOB87319,
BCP05688,
KS-00000M2I,
2447AH,
BDBM50059637,
MFCD22417098,
s8002,
ZINC77024226,
AKOS026750339,
BCP9000741,
CS-0747,
DB11795,
SB16472,
NCGC00345796-01,
NCGC00345796-10,
2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-morpholino-benzimidazole-4-carboxylic acid,
AS-17013,
BC600347,
HY-15245,
SMR004702946,
FT-0700179,
SW219650-1,
W-5929,
J-690147,
1372540-91-4,
2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxy,
Acalabrutinib,
D0G3MN,
cc-414,
C22H22F3N3O3,
ACN-039805,
B2186,
A11784,
1H-Benzimidazole-4-carboxylic acid, 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-,
2-Methyl-1-[2-methyl-3-(trifluoromethyl)benzyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid,